Financial Performance - The company's revenue for Q3 2024 was ¥132,486,799.05, a decrease of 13.08% compared to ¥152,425,421.92 in the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥11,619,913.07, down 52.92% from ¥24,683,267.02 year-on-year[2] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥10,544,926.60, a decline of 46.24% compared to ¥19,571,541.85 in the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.0808, down 52.47% from ¥0.2204 in the same quarter last year[2] - Total operating revenue for the current period is ¥340,192,520.78, a decrease of 9.2% from ¥374,640,349.93 in the previous period[19] - Net profit for the current period is ¥31,611,622.21, representing a decline of 36.5% compared to ¥49,776,443.87 in the previous period[20] - Operating profit decreased to ¥34,737,007.80, down 33.4% from ¥52,179,722.54 in the previous period[20] - Basic earnings per share decreased to ¥0.2190, down 36.2% from ¥0.3428 in the previous period[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥838,823,832.71, a decrease of 6.78% from ¥781,919,613.79 at the end of the previous year[2] - As of the end of Q3 2024, total current assets decreased to CNY 512,278,106.91 from CNY 560,530,252.86 at the beginning of the period, a decline of approximately 8.6%[16] - The company's total assets decreased to CNY 781,919,613.79 from CNY 838,823,832.71, a decline of about 6.8%[17] - Total liabilities increased to CNY 41,867,280.26 from CNY 39,718,587.17, reflecting an increase of approximately 5.4%[17] - The company's equity attributable to shareholders decreased to CNY 740,052,333.53 from CNY 799,105,245.54, a decrease of approximately 7.4%[18] Cash Flow - Cash flow from operating activities for the year-to-date period increased by 73.80% to ¥44,830,939.75 compared to ¥25,794,476.29 in the previous year[2] - Net cash flow from operating activities increased by 73.80% to 44,830,939.75 CNY, attributed to a reduction in cash payments for raw materials[9] - Cash flow from operating activities is ¥343,529,888.82, a decrease of 17.6% from ¥416,895,512.53 in the previous period[21] - The net cash flow from operating activities for Q3 2024 was ¥44,830,939.75, an increase of 73.7% compared to ¥25,794,476.29 in Q3 2023[22] - Cash outflow from operating activities totaled ¥308,950,247.42, a decrease of 23.3% compared to ¥402,860,089.56 in Q3 2023[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,928, with the largest shareholder holding 38.24% of the shares[10] - The largest shareholder, Hong Wei, holds 55,527,272 shares, representing 38.24% of the total shares[10] - The company repurchased 2,120,665 shares, accounting for 1.46% of the total share capital[11] - The total number of restricted shares at the beginning of the period was 59,808,045, with 17,632,939 shares added during the period[12] - The net cash flow from financing activities decreased by 99.90% to -91,208,757.63 CNY, mainly due to increased dividend and stock repurchase expenditures[10] Investment and R&D - The company plans to establish a wholly-owned subsidiary to invest in a 100,000-ton corn protein processing project, aiming to enhance its competitive advantage in the domestic feed enzymatic protein sector and expand new revenue growth points[13] - The company and its subsidiaries added 6 new patents from July to September 2024, including devices for quantitative feeding and cooling systems[14] - Research and development expenses for the current period are ¥14,506,680.38, down 9.7% from ¥16,061,814.55 in the previous period[19] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 1.56%, down from 3.15% in the same period last year[2] - Financial expenses decreased by 43.10% to -2,289,772.03 CNY compared to the previous period, primarily due to changes in exchange gains[8] - Investment income dropped by 77.26% to 687,197.10 CNY, mainly due to changes in the profitability of associated companies[8] - The fair value change income increased significantly by 2461.10% to 727,222.25 CNY, primarily due to changes in the fair value of shares in Shanghai Nongcun Commercial Bank[8] - The company reported a tax expense of ¥4,568,832.45, down from ¥6,095,796.82 in the previous period[20] - The company received ¥4,893,748.11 in tax refunds, up 36.2% from ¥3,593,340.36 in Q3 2023[22] Compliance and Recognition - The company was recognized as a "Shanghai Contract-abiding and Trustworthy Benchmark Enterprise" in August 2024 due to its standardized management and good market reputation[15] Changes in Cash and Cash Equivalents - The company’s cash and cash equivalents at the end of the reporting period were ¥248,647,790.61, a decrease of 30.90% from ¥359,853,060.69 at the end of the previous year[6] - Cash and cash equivalents at the end of Q3 2024 amounted to ¥248,647,790.61, a decrease from ¥309,903,573.02 at the end of Q3 2023[22]
美农生物(301156) - 2024 Q3 - 季度财报